Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics (Premium)
$10.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc Announces Receipt of Approval From Antimonopoly Committee of Ukraine for Acquisition of Obagi Medical Products Inc


Wednesday, 24 Apr 2013 08:01am EDT 

Valeant Pharmaceuticals International Inc announced that it has received approval by the Antimonopoly Committee of Ukraine (the AMC) of its proposed acquisition of Obagi Medical Products Inc (Obagi) pursuant to a tender offer and subsequent merger. The receipt of the AMC's approval of the acquisition satisfies one of the conditions to consummate the tender offer. As previously announced, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired. The consummation of the tender offer remains subject to other customary conditions, all of which the parties expect to be satisfied. The tender offer for all of the outstanding shares of common stock of Obagi at a price of $24.00 per share, net to the seller in cash, without interest (less any required withholding taxes) expires at 12:00 midnight, New York City time, on April 25, 2013 (which is one minute after 11:59 p.m.New York City time on April 24, 2013). Valeant does not expect to further extend the offer and expects to complete the acquisition of Obagi on April 25, 2013 or shortly thereafter. 

Company Quote

113.77
0.67 +0.59%
21 Aug 2014